BEAM Stock: Price, Earnings History and SEC Filings
Beam Therapeutics Inc. (BEAM) last traded at $27.23, down 5.58% on the latest session and up 11.4% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-1.18 against an analyst estimate of $-1.00, a miss of 18.0%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
BEAM earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 4, 2026 | $-1.18 | $-1.00 | -18.00% |
| Mar 2026 | May 7, 2026 | $-0.91 | $-0.87 | -4.60% |
| Dec 2025 | Feb 24, 2026 | $-0.10 | $-1.13 | +91.15% |
| Sep 2025 | Nov 4, 2025 | $-1.10 | $-0.98 | -12.24% |
BEAM beat the analyst EPS estimate in 1 of its last 4 reported quarters. Source: Nasdaq.
How BEAM reacts to earnings
Across its last 8 earnings releases, BEAM moved 9.9% on average the next session, in either direction. It rose after 3 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-04 | Before open | +9.42% |
| 2026-05-07 | Before open | -2.69% |
| 2026-02-24 | Before open | +13.98% |
| 2026-01-12 | Before open | +22.29% |
| 2025-11-04 | Before open | -6.23% |
| 2025-08-05 | Before open | -2.20% |
| 2025-05-06 | Before open | -19.32% |
| 2025-02-25 | Before open | -3.09% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
BEAM financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $140M | -$80M | -$360M | -57.2% | $-0.81 |
| 2024 | $64M | -$377M | -$356M | -593.1% | $-4.58 |
| 2023 | $378M | -$133M | -$183M | -35.1% | $-1.72 |
| 2022 | $61M | -$289M | -$26M | -474.5% | $-4.13 |
| 2021 | $52M | -$371M | -$113M | -714.9% | $-5.77 |
| 2020 | $24000 | -$195M | -$112M | -810800.0% | $-4.19 |
| 2019 | $18000 | -$78M | -$85M | -435144.4% | $-14.05 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for BEAM
- 10-Q · Aug 4, 2026
- 8-K · Aug 4, 2026Results of operations, Financial statements and exhibits
- 8-K · Jun 8, 2026Shareholder vote
- 10-Q · May 7, 2026
- 8-K · May 7, 2026Results of operations, Financial statements and exhibits
- DEF 14A · Apr 17, 2026
- 8-K · Mar 5, 2026Agreement terminated
- 10-K · Feb 24, 2026
- 8-K · Feb 24, 2026Material agreement, Results of operations, New financial obligation
- 8-K · Feb 12, 2026Material agreement, Financial statements and exhibits
Insider filing activity
BEAM insiders filed 3 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
BEAM news
- Cathie Wood Loads Up On TEM, ILMN And Biotech Stocks — But Pares Stake In This Pharma Giant That Had A Blowout Q3Oct 31, 2026 · stocktwits.com
- 3 Promising Genomics Stocks to Add to Your Portfolio NowOct 30, 2026 · finance.yahoo.com
- Global Gene Writing Technology Market Report 2026: Size, Trends, and Forecast to 2030 | Capitalize on 24.8% CAGR with Beam, Twist Bioscience, Tessera, and IntelliaOct 29, 2026 · finance.yahoo.com
- Monte Rosa Therapeutics (GLUE) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseOct 29, 2026 · finance.yahoo.com
- Why Beam Therapeutics Stock Is Up 15.6% And What's NextOct 29, 2026 · finance.yahoo.com
- Beam Therapeutics (BEAM) Moves 15.6% Higher: Will This Strength Last?Oct 29, 2026 · finance.yahoo.com
- BEAM Stock Climbs On First Look At One-Time GSDIa Gene Fix; H.C. Wainwright Sees Further 200% UpsideOct 27, 2026 · stocktwits.com
- Beam Therapeutics Reports Early BEAM-301 Gains in GSD1a Fasting ToleranceOct 27, 2026 · marketbeat.com
About Beam Therapeutics Inc.
Beam Therapeutics Inc. (BEAM) is a US-listed public company on Nasdaq. The SEC classifies its business as Biological Products (no Diagnostic Substances). It is incorporated in DE. Its fiscal year ends in December.